Selexipag

Selexipag is a selective lipid mediator receptor agonist, specifically targeting the IP receptor (prostacyclin). It is primarily used for the treatment of pulmonary arterial hypertension (PAH), a condition characterized by an abnormally high blood pressure within the arteries that supply blood to the lungs. This can lead to shortness of breath, fatigue, and other debilitating symptoms.
Selexipag works by mimicking the effects of prostacyclin, a naturally occurring substance in the body that helps to relax and widen the blood vessels, thereby reducing blood pressure and increasing blood flow. By selectively binding to the IP receptor, it promotes the production of cGMP, a signaling molecule responsible for smooth muscle relaxation and vasodilation.
The medication is available as a tablet for oral administration. Treatment with Selexipag should be initiated and closely supervised by a healthcare professional experienced in managing pulmonary arterial hypertension. The dosage should be individually tailored to the patient’s condition and response to treatment, and it should be taken consistently to maintain effectiveness.
Common side effects associated with Selexipag treatment may include headache, diarrhea, and joint pain. More serious side effects, such as an increased risk of bleeding or infection, should also be monitored. As with all medications, patients should consult their healthcare provider if they experience any adverse reactions.